<unk> , sold under the brand name Ocrevus, is a pharmaceutical drug for the treatment of multiple sclerosis (MS). It is a humanized anti-CD20 monoclonal antibody. It targets CD20 marker on B lymphocytes and hence is an immunosuppressive drug.<unk>  binds to an epitope that overlaps with the epitope to which rituximab binds. It was approved by the U.S. Food and Drug Administration (FDA) in March 2017, and the first FDA approved drug for the primary progressive form of MS; it was discovered and developed and is marketed by Hoffmann–La Roche's subsidiary Genentech under the trade name Ocrevus. With the approval, the FDA also required the company to conduct several Phase IV clinical trials to better understand whether the drug is safe and effective in young people, cancer risks, and effects on pregnant women and children they might bear. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.
Ocrelizumab
Risankizumab
Ibalizumab
Theralizumab
Brolucizumab
Atezolizumab
Inebilizumab
Etaracizumab